S&P 500 Healthcare Sector SEC Filings — February 25, 2026

26-02-2026

26-02-2026

BeOne Medicines Ltd. filed an 8-K on February 26, 2026 (AccNo: 0001628280-26-011941), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons were disclosed in the filing summary. The filing size is 2 MB, with sector not specified.

26-02-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. Critical event content is missing, limiting assessment of impact.

26-02-2026

News Corp filed a Form 8-K on February 26, 2026, reporting Other Events under Item 8.01 and attaching Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the other events, financial statements, or exhibits are disclosed in the filing summary. This is a multi-item informational filing with no quantified metrics or directional impacts provided.

26-02-2026

Ellington Financial Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific quantitative metrics, comparisons, or guidance in the available information. No positive, negative, or flat performance indicators are detailed.

26-02-2026

Integra LifeSciences Holdings Corp filed an 8-K on February 26, 2026, reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits provided under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the filing details provided. This appears to be a standard earnings-related disclosure without detailed performance data available.

26-02-2026

International Paper Co /NEW/ filed an 8-K on February 26, 2026, reporting under Item 7.01 Regulation FD Disclosure. No specific financial metrics, transactions, events, or quantitative data are explicitly stated in the provided filing information. This is a voluntary disclosure with no details on positive or negative impacts available.

26-02-2026

Niagen Bioscience, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001386570-26-000003, Size: 162 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the core events, transactions, financial impacts, or exhibits provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons are disclosed.

26-02-2026

Wave Life Sciences Ltd. filed an 8-K on 2026-02-26 furnishing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, or period-over-period comparisons were disclosed in the provided filing information. Sector not specified.

26-02-2026

Bread Financial Holdings, Inc. filed an 8-K on February 26, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific events, transactions, financial metrics, or quantitative data are disclosed in the filing summary provided. Critical details such as core events, dollar values, or performance metrics are NOT_DISCLOSED.

26-02-2026

ACI Worldwide, Inc. filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details on the officer involved, nature of the change, financial metrics, or any quantitative data are disclosed in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

26-02-2026

MVB Financial Corp filed an 8-K on 2026-02-26 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, with financial statements and exhibits under Item 9.01. No specific details on the agreement, obligation size, terms, or financial impacts are disclosed in the provided information. This represents a multi-item mandatory disclosure with potential balance sheet implications, but lacks quantification.

26-02-2026

CACI International Inc. filed a Form 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed in the provided filing summary. This appears to be a multi-item informational filing with no quantified metrics or directional impacts mentioned.

26-02-2026

Disc Medicine, Inc. filed an 8-K on February 26, 2026, under Item 2.02 announcing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. This constitutes a standard earnings-related disclosure without quantified metrics.

26-02-2026

Edgewise Therapeutics, Inc. filed an 8-K on 2026-02-26 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or other quantitative financial data are mentioned in the filing description. This appears to be a standard voluntary quarterly financial results disclosure.

26-02-2026

Arrow Financial Corp filed a Form 8-K on February 26, 2026 (AccNo: 0000717538-26-000030, Size: 48 MB), reporting under Item 1.01 entry into a material definitive agreement, Item 7.01 Regulation FD disclosure, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No quantitative metrics, transaction details, financial impacts, or period-over-period comparisons are disclosed. The large filing size suggests substantial exhibits, likely including the agreement text.

26-02-2026

Bank of New York Mellon Corp filed an 8-K on February 26, 2026, reporting solely under Item 8.01 Other Events. No details on the specific event, financial impacts, transactions, or metrics are disclosed in the provided filing information. No positive or negative metrics are mentioned.

26-02-2026

Manhattan Associates Inc filed an 8-K on February 26, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

26-02-2026

Hudson Pacific Properties, Inc. filed an 8-K on 2026-02-26 reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance are NOT_DISCLOSED in the provided information.

26-02-2026

Pathward Financial, Inc. filed an 8-K on February 26, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the events, transactions, financial metrics, or exhibits provided in the disclosure summary. No quantitative impacts, positive or negative metrics, or strategic implications are disclosed.

26-02-2026

Elevance Health, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 7.01 (Regulation FD Disclosure). No specific details on the affected officer, position, reason for change, or compensatory arrangements are provided in the filing summary. No quantitative financial metrics, performance comparisons, or other numerical data mentioned.

26-02-2026

CoreWeave, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001769628-26-000094), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. Sector details are NOT_DISCLOSED.

• ·Multi-item 8-K filing (Items 2.02 and 9.01)
• ·Event type: Financial Results
• ·Source: US SEC, Size: 545 KB

26-02-2026

TFS Financial CORP filed a Form 8-K on 2026-02-26 under Item 8.01 Other Events. No specific details regarding the core event, financial impacts, transaction values, metrics, or scheduled events are disclosed in the provided filing information. This is a single-item voluntary disclosure with no quantitative data available.

26-02-2026

Pacira BioSciences, Inc. filed an 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other financial metrics are detailed in the provided filing information. This appears to be a standard earnings-related disclosure without quantified positives, negatives, or flat performance indicators.

26-02-2026

National CineMedia, Inc. filed a Form 8-K on 2026-02-26 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. No specific financial metrics, revenue, earnings, comparisons, or guidance are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed quantitative data.

26-02-2026

Caris Life Sciences, Inc. filed an 8-K on February 26, 2026 (AccNo: 0002019410-26-000011), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but no specific revenue, earnings, or other quantitative metrics are provided in the available information. No positive or negative performance indicators, comparisons, or guidance changes are mentioned.

26-02-2026

Mind Medicine (MindMed) Inc. filed an 8-K on February 26, 2026 (AccNo: 0001193125-26-076612), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are mentioned. This is a standard earnings-related disclosure in the healthcare/biotech sector implied by company name, but sector explicitly not specified.

26-02-2026

Castle Biosciences Inc filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item filing typical for earnings releases.

26-02-2026

Sprout Social, Inc. filed a Form 8-K on 2026-02-26 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. This is a multi-item filing typical for quarterly earnings releases. Specific financial metrics, period-over-period comparisons, guidance, or other quantitative data are NOT_DISCLOSED.

26-02-2026

STIFEL FINANCIAL CORP filed an 8-K on February 26, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details, financial metrics, transactions, or events are disclosed in the filing metadata provided.

26-02-2026

Alerus Financial Corp filed an 8-K on February 26, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are provided in the filing summary. This appears to be an informational filing with no quantified metrics or directional impacts disclosed.

26-02-2026

MidCap Financial Investment Corp filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076894, Size: 407 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but no specific revenue, earnings, balance sheet changes, guidance, period-over-period comparisons, or other quantitative metrics were disclosed in the provided filing details. No positive, negative, or flat performance indicators were mentioned.

• ·Filing Accession Number: 0001193125-26-076894
• ·Filing Size: 407 KB

26-02-2026

Oportun Financial Corp filed an 8-K on February 26, 2026, disclosing under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, or quantitative data such as revenue, earnings, or guidance are mentioned in the filing details provided. This represents a standard earnings-related disclosure without disclosed positives, negatives, or flat performance indicators.

26-02-2026

Revelation Biosciences, Inc. filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-076833), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were disclosed in the provided filing information. The filing size is 443 KB, with sector not specified.

26-02-2026

InPoint Commercial Real Estate Income, Inc. filed a Form 8-K on February 26, 2026, under Item 8.01 Other Events. No specific details regarding the nature of the event, transaction values, financial metrics, or other quantitative data are disclosed in the provided filing metadata. This is a single-item filing with no mentioned positive or negative performance indicators.

26-02-2026

Cytek Biosciences, Inc. filed an 8-K on February 26, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. No positive or negative performance indicators, period-over-period comparisons, or balance sheet details are available.

26-02-2026

Abbott Laboratories filed an 8-K on 2026-02-26 reporting Item 1.01 Entry into a Material Definitive Agreement and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are disclosed. This is a mandatory disclosure of a material event without quantified positive or negative elements.

26-02-2026

Lamar Advertising Co/NEW filed an 8-K on 2026-02-26 under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or exhibits are disclosed in the provided filing information. This is a multi-item filing with no quantitative metrics, transactions, or performance data mentioned.

26-02-2026

BROADWAY FINANCIAL CORP DE filed an 8-K on February 26, 2026, under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events, transactions, financial metrics, or exhibits are disclosed in the filing summary. No quantitative data, comparisons, or directional impacts provided.

26-02-2026

Proficient Auto Logistics, Inc. filed an 8-K on 2026-02-26 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure in Item 7.01 and Financial Statements and Exhibits in Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, timing, or any quantitative impacts are disclosed. No positive or negative metrics are provided, resulting in purely informational disclosure.

26-02-2026

Avidity Biosciences, Inc. filed a Form 8-K on February 26, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders. No specific details on the matters voted upon, vote results, outcomes, or any quantitative data are disclosed in the provided filing information. This filing is informational in nature with no financial metrics, strategic implications, or directional impacts mentioned.

26-02-2026

Columbus Circle Capital Corp II filed an 8-K on February 26, 2026, disclosing Other Events under Item 8.01 and attaching Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibits are provided in the filing summary. This is a multi-item, likely voluntary disclosure as Item 8.01 covers events not specified elsewhere.

26-02-2026

NewMarket Corp filed a Form 8-K on February 26, 2026 (AccNo: 0001193125-26-077261, Size: 143 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, transactions, financial metrics, or exhibits are disclosed in the provided filing summary. This appears to be an informational filing with no quantified positive or negative impacts mentioned.

26-02-2026

Skyward Specialty Insurance Group, Inc. filed an 8-K on 2026-02-26 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific names, positions affected, reasons for change, timing, or quantitative details are disclosed.

26-02-2026

Civista Bancshares, Inc. filed an 8-K on 2026-02-26 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on positions affected, names, reasons, timing, or any quantitative metrics are disclosed.

26-02-2026

AbbVie Inc. filed an 8-K on February 26, 2026 (AccNo: 0001104659-26-020643, Size: 558 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific other events or contents of the exhibits are disclosed. This appears to be a multi-item informational filing with no quantitative metrics, positive or negative performance indicators, or directional implications provided.

26-02-2026

Boston Scientific Corp filed a multi-item 8-K on February 26, 2026, disclosing entry into a material definitive agreement (Item 1.01) while terminating a prior material definitive agreement (Item 1.02). The filing also reports the creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), with financial statements and exhibits under Item 9.01. No specific transaction values, parties, terms, or financial impacts are disclosed.